Causeway Capital Management LLC Grows Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Causeway Capital Management LLC boosted its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 400.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 539,305 shares of the company's stock after acquiring an additional 431,444 shares during the quarter. Causeway Capital Management LLC owned 0.06% of Dr. Reddy's Laboratories worth $8,516,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its stake in Dr. Reddy's Laboratories by 423.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock valued at $29,000 after purchasing an additional 1,507 shares during the period. Glass Jacobson Investment Advisors llc increased its stake in Dr. Reddy's Laboratories by 400.0% in the 4th quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock worth $32,000 after acquiring an additional 1,600 shares during the last quarter. POM Investment Strategies LLC raised its position in shares of Dr. Reddy's Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after buying an additional 1,820 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in Dr. Reddy's Laboratories by 461.0% in the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock worth $40,000 after buying an additional 2,093 shares in the last quarter. Finally, Sierra Ocean LLC bought a new position in shares of Dr. Reddy's Laboratories during the 4th quarter valued at $43,000. Hedge funds and other institutional investors own 3.85% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Nomura cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th.

Dr. Reddy's Laboratories Stock Up 1.8 %

Dr. Reddy's Laboratories stock traded up $0.25 during trading hours on Friday, hitting $13.69. 2,412,404 shares of the stock traded hands, compared to its average volume of 1,435,918. The company has a market cap of $11.42 billion, a PE ratio of 21.79 and a beta of 0.51. The firm's 50-day moving average price is $13.16 and its two-hundred day moving average price is $14.31. Dr. Reddy's Laboratories Limited has a one year low of $12.26 and a one year high of $16.89. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, research analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.